Literature DB >> 14671394

Ascertainment and treatment of delayed puberty.

Jesús Pozo1, Jesús Argente.   

Abstract

The majority of patients with pubertal delay, can be classified as having primary pubertal delay (constitutional delay of growth and puberty, CDGP), although any child with a chronic disease could present with delayed puberty. In contrast, children with hypogonadism, either hyper- or hypogonadotropic, exhibit a total absence of pubertal development. Hence, early evaluation of these patients should be performed. Delay of puberty leads to psychological problems, secondary to short stature and/or delay in the acquisition of secondary sex characteristics and the reduction of bone mass. Although the final height in patients with CDGP is usually normal, some of these patients do not reach the third percentile or remain in the lowest part of the growth chart according to familial height. The most common reason for treating CDGP patients, usually with sex steroids, is for psychological difficulties and for loss of bone mineralization. Treatment must be individualized. Therapeutic options and new drugs will be discussed. Appropriate treatment and adequate nutritional intake are indicated in patients with delayed puberty due to chronic illness. In patients with hypo- or hypergonadotropic hypogonadism, puberty must be induced or completed. Different treatments (GnRH analogues, gonadotropins and sex steroids), and the main objectives are discussed. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14671394     DOI: 10.1159/000074498

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  7 in total

1.  High-flow priapism in testosterone-treated boys with constitutional delay of growth and puberty may occur even when very low doses are used.

Authors:  T Arrigo; G Crisafulli; G Salzano; G Zirilli; F De Luca
Journal:  J Endocrinol Invest       Date:  2005-04       Impact factor: 4.256

2.  Adult height in children with short stature and idiopathic delayed puberty after different management.

Authors:  Stefano Zucchini; Malgorzata Wasniewska; Mariangela Cisternino; Mariacarolina Salerno; Lorenzo Iughetti; Mohamad Maghnie; Maria Elisabeth Street; Manuela Caruso-Nicoletti; Stefano Cianfarani
Journal:  Eur J Pediatr       Date:  2007-08-24       Impact factor: 3.183

Review 3.  Hypopituitarism.

Authors:  Paola Ascoli; Francesco Cavagnini
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

4.  Thalassaemia and aberrations of growth and puberty.

Authors:  Andreas Kyriakou; Nicos Skordis
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-07-27       Impact factor: 2.576

Review 5.  ENDO-ERN expert opinion on the differential diagnosis of pubertal delay.

Authors:  Luca Persani; Marco Bonomi; Martine Cools; Mehul Dattani; Leo Dunkel; Claus H Gravholt; Anders Juul
Journal:  Endocrine       Date:  2021-01-29       Impact factor: 3.633

6.  Progression of puberty after initiation of androgen therapy in patients with idiopathic hypogonadotropic hypogonadism.

Authors:  Bindu Kulshreshtha; Rajesh Khadgawat; Nandita Gupta; Ariachery Ammini
Journal:  Indian J Endocrinol Metab       Date:  2013-09

7.  Characteristics of Selected Somatic and Motor Abilities of Youth Soccer Players with Diabetes Type 1 Treated with Insulin Pump Therapy.

Authors:  Magdalena Krzykała; Katarzyna Domaszewska; Małgorzata Woźniewicz-Dobrzyńska; Jakub Kryściak; Agata Konarska; Aleksandra Araszkiewicz; Dorota Zozulińska-Ziółkiewicz; Andrzej Gawrecki; Grzegorz Biegański; Jan M Konarski
Journal:  Int J Environ Res Public Health       Date:  2021-03-27       Impact factor: 3.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.